Frontlight ResearchEarly access
Childhood cancers trials in Canada
110 of 152 trials · From ClinicalTrials.gov, checked 18 November 2026. Ask the study team whether a trial fits you.
- Phase 1/2Taking peopleThe Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
- Where
- Calgary, Edmonton, Halifax, London, Montreal, Ottawa, Québec, Sherbrooke, Toronto, Vancouver, Winnipeg
- Age
- Up to 22 years
- People
- 960 worldwide
- Run by
- PedAL BCU, LLC
See details and how to joinNCT04726241 - Phase 1Taking peopleStudy of Lunresertib Alone or in Combination With RP-3500 or Zedoresertib (Debio 0123) in Patients With Advanced Solid Tumors
- Where
- Montreal, Toronto
- Age
- 12 years and over
- People
- 464 worldwide
- Run by
- Debiopharm International SA
See details and how to joinNCT04855656 · EU 2023-510063-35-00 - Phase 2Taking peopleACT001 for the Treatment of Diffuse Intrinsic Pontine Gliomas and H3K27-altered High Grade Gliomas
- Where
- Montreal, Toronto
- Age
- 12 months to 39 years
- People
- 60 worldwide
- Run by
- Nationwide Children's Hospital
See details and how to joinNCT06838676 - Phase 2Taking peopleBelzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)
- Where
- Calgary, Toronto
- Age
- 12 years and over
- People
- 355 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT04924075 · EU 2023-504853-11-00 - Phase 1/2Taking peopleStudy of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Acute Lymphoblastic Leukemia
- Where
- Toronto, Vancouver
- Age
- 12 years and over
- People
- 83 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07109219 · EU 2025-522372-93-00 - Phase 2Taking peopleA Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
- Where
- Calgary, Edmonton, Halifax, Montreal, Québec, Sherbrooke, St. John's, Vancouver, Winnipeg
- Age
- 1 year to 30 years
- People
- 461 worldwide
- Run by
- National Cancer Institute (NCI)
See details and how to joinNCT04546399 - Phase 3Taking peopleA Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab
- Where
- Calgary, Edmonton, Halifax, Hamilton, London, Montreal, Ottawa, Québec, Saskatoon, Sherbrooke, Toronto, Vancouver, Winnipeg
- Age
- 5 years to 60 years
- People
- 1,875 worldwide
- Run by
- National Cancer Institute (NCI)
See details and how to joinNCT05675410 - Phase 1/2Not yet taking people in CanadaTINI 2: Total Therapy for Infants With Acute Lymphoblastic Leukemia II
- Where
- Calgary, Edmonton, Hamilton, Montreal, Québec, Vancouver
- Age
- Up to 1 year
- People
- 90 worldwide
- Run by
- Tanja Andrea Gruber
See details and how to joinNCT05848687 - Phase 1/2Taking peopleSilmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors
- Where
- Montreal, Sherbrooke
- Age
- Up to 30 years
- People
- 104 worldwide
- Run by
- Milton S. Hershey Medical Center
See details and how to joinNCT06541262 - Phase 1/2Not yet taking people in CanadaTrial of 225Ac-DOTATATE (RYZ101) in Subjects With ER+, HER2-negative Unresectable or Metastatic Breast Cancer Expressing SSTRs.
- Where
- Québec, Toronto, Victoria
- People
- 64 worldwide
- Run by
- RayzeBio, Inc.
See details and how to joinNCT06590857 - Phase 1Taking peopleGCAR1, a Chimeric Antigen Receptor (CAR) T-CELL Therapy for Relapsed/Refractory GPNMB-Expressing Solid Tumours
- Where
- Calgary, Montreal, Ottawa, Toronto
- Age
- 15 years and over
- People
- 30
- Run by
- Canadian Cancer Trials Group
See details and how to joinNCT07297667 - Phase 4Taking peopleDabrafenib and/or Trametinib Rollover Study
- Where
- Toronto
- Age
- 18 years to 100 years
- People
- 100 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT03340506 · EU 2023-509318-13-00 - Phase 3Taking peopleStudy of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (eVOLVE-Cervical)
- Where
- Hamilton, London, Montreal, Ste-Foy, Toronto
- Age
- 15 years and over
- People
- 800 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT06079671 · EU 2023-504374-38-00 - Phase 2Taking peopleStudy to Determine the Efficacy and Safety of Asciminib in Pediatric Patients With Ph+ CML-CP
- Where
- Edmonton, Montreal
- Age
- 1 year to 18 years
- People
- 50 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT07354074 - Phase 2/3Taking peopleA Clinical Trial of MK-1045 in People With B-cell Acute Lymphoblastic Leukemia (MK-1045-005)
- Where
- Toronto
- Age
- 12 years and over
- People
- 340 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT07570173 · EU 2025-522267-15-00 - Phase 4Taking peopleAsciminib Roll-over Study
- Where
- Montreal
- Age
- 7 years to 100 years
- People
- 347 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT04877522 · EU 2023-507557-16-00 - Phase 1/2Taking peopleA Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)
- Where
- Edmonton, Ottawa, Toronto, Vancouver
- Age
- 12 years and over
- People
- 840 worldwide
- Run by
- Nuvalent Inc.
See details and how to joinNCT05384626 · EU 2024-514266-39-00 - Phase 3Taking peopleA Rollover Study for Participants Previously Enrolled in a Genentech and/or F. Hoffman-La Roche Sponsored Study
- Where
- Toronto
- People
- 200 worldwide
- Run by
- Hoffmann-La Roche
See details and how to joinNCT05862285 · EU 2023-504263-16-00 - Phase 1/2Taking peopleStudy of Lurbinectedin Monotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Ewing Sarcoma
- Where
- Toronto
- Age
- 2 years to 30 years
- People
- 60 worldwide
- Run by
- Jazz Pharmaceuticals
See details and how to joinNCT05734066 - Phase 1/2Taking peopleA Phase 1/2 Study of Bleximenib in Participants With Acute Leukemia (cAMeLot-1)
- Where
- Montreal, Toronto, Vancouver
- Age
- 2 years and over
- People
- 420 worldwide
- Run by
- Janssen Research & Development, LLC
See details and how to joinNCT04811560 · EU 2023-506581-31-00 - Phase 2/3Taking peopleLong-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells
- Where
- Calgary, Hamilton, Montreal, Toronto, Vancouver
- People
- 1,541 worldwide
- Run by
- Celgene
See details and how to joinNCT03435796 · EU 2023-504201-36-00 - Early phase 1Taking peoplePilot Study of IT Topotecan and Maintenance Chemotherapy for HR-EBTs in Children < 6 Years, Post Consolidation
- Where
- Calgary, Edmonton, Halifax, Hamilton, London, Montreal, Ottawa, Québec, Sherbrooke, Toronto, Vancouver, Winnipeg
- Age
- Up to 6 years
- People
- 15
- Run by
- C17 Council
See details and how to joinNCT06942039 - Phase 3Taking peopleDinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma
- Where
- Calgary, Edmonton, Halifax, Hamilton, London, Montreal, Ottawa, Québec, Saskatoon, Sherbrooke, St. John's, Toronto, Vancouver, Winnipeg
- Age
- Up to 30 years
- People
- 478 worldwide
- Run by
- National Cancer Institute (NCI)
See details and how to joinNCT06172296 - Phase 1/2Taking peopleSubstudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
- Where
- Calgary, Montreal, Toronto
- Age
- 6 months to 25 years
- People
- 90 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06395103 · EU 2023-507178-41-00 - Phase 2Not yet taking people in CanadaAdaptive Radiotherapy for Safe Hypofractionation
- Where
- Montreal
- People
- 264
- Run by
- Centre hospitalier de l'Université de Montréal (CHUM)
See details and how to joinNCT07516210